Valdecoxib chemical structure
Find information on thousands of medical conditions and prescription drugs.

Bextra

Valdecoxib is a prescription drug used in the treatment of osteoarthritis, rheumatoid arthritis, and painful menstruation and menstrual symptoms. It is classified as a nonsteroidal anti-inflammatory drug, or NSAID, and should not be taken by anyone allergic to these types of medications. more...

Home
Diseases
Medicines
A
B
Baciim
Bacitracin
Baclofen
Bactrim
Bactroban
Barbexaclone
Barbital
Baros
Basiliximab
Baycol
Beclamide
Beclometasone
Beclovent
Beconase
Beldin
Benadryl
Benazepril
Bendroflumethiazide
Benserazide
Bentiromide
Benylin
Benzaclin
Benzalkonium chloride
Benzocaine
Benzonatate
Betacarotene
Betadine
Betahistine
Betamethasone
Betaxolol
Bextra
Biaxin
Bibrocathol
Bicalutamide
Bicillin
Biclotymol
Biotin
Bisoprolol
Bleomycin
Blocadren
Boldenone
Boniva
Bontril
Bosentan
Bravelle
Brethaire
Brevibloc
Brevicon
Bricanyl
Bromazepam
Bromelain
Bromhexine
Bromocriptine
Brompheniramine
Bronkodyl
Bronopol
BSS
Bucet
Budesonide
Bumetanide
Bupivacaine
Buprenex
Buprenorphine
Buserelin
Buspar
Buspirone
Busulfan
Butalbital
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Valdecoxib was manufactured and marketed under the brand name Bextra® by G. D. Searle & Company. It was available by prescription in tablet form until 2005, when it was removed from the market due to concerns about possible increased risk of heart attack and stroke.

Uses

Since its registration, Bextra was prescribed for pain associated with arthritis, menstrual discomfort, and other ailments.

Side-effects and withdrawal

On April 7, 2005, Pfizer withdrew Bextra from the US market on recommendation by the FDA, citing an increased risk of heart attack and stroke and also the risk of a serious, sometimes fatal, skin reaction. This was a result of recent attention to prescription NSAIDs, such as Merck's Vioxx. Other reported side-effects were angina and Stevens-Johnson syndrome.

Pfizer first acknowledged cardiovascular risks associated with Bextra in October of 2004. The American Heart Association soon after was presented with a report indicating patients using Bextra while recovering from heart surgery were 2.19 times more likely to suffer a stroke or heart attack than those taking placebos.

Personal injury

With the removal of the drug from the market, there is expected to be a surge in personal injury claims, many in the form of class action, to seek compensation.

Read more at Wikipedia.org


[List your site here Free!]


Adverse events lead to warning on Bextra label - Dysmenorrhea Treatment
From OB/GYN News, 1/15/03 by Deeanna Franklin

Postmarketing reports of adverse events have led the Pharmacia Corp. to issue a warning letter to health care professionals, alerting them to changes in the product labeling for valdecoxib tablets (Bextra).

Valdecoxib is indicated for the treatment of dysmenorrhea and relief of symptoms of osteoarthritis and rheumatoid arthritis.

The labeling changes for Bextra include a warning regarding the risk of serious skin reactions, including Stevens-Johnson syndrome, exfoliative dermatitis, toxic epidermal necrolysis, and erythema multi-forme. There also have been some reports of hypersensitivity reactions, such as anaphylaxis and angioedema.

These adverse events were rare, but some of the cases reported were serious and life threatening and resulted in hospitalizations. The reactions also occurred in patients with and without a history of allergic-type reactions to sulfonamides, according to the letter to health care professionals.

The Contraindications and Warnings sections of the label have been revised; the postmarketing experience is detailed in the Adverse Reactions section.

"Bextra should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity," the manufacturer advised in the letter.

Copies of the letter can be viewed at the Food and Drug Administration's MedWatch Web site, www.fda.gov/medwatch/safety/2002/bextra.htm.

Any unexpected adverse or serious events associated with the use of Bextra can be reported to Pharmacia at 800-323-4204 or to the FDA MedWatch program at 800-FDA-1088.

COPYRIGHT 2003 International Medical News Group
COPYRIGHT 2003 Gale Group

Return to Bextra
Home Contact Resources Exchange Links ebay